Glioma
📧 Sign up to get email alerts when something new happens for Glioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy [Phase 4]
A Phase 4 clinical trial sponsored by Mayo Clinic comparing telehealth and in-person assessments in glioma patients undergoing oral chemothe…
-
CLINICAL_TRIALS trial_result · 2025-12-26Clinical Trial Update: Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent [Phase 2]
Phase 2 ascending-dose study of RVP-001, a manganese-based MRI contrast agent, completed to assess safety and preliminary efficacy in CNS le…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors [Phase 1]
Phase 1 trial evaluating locoregional EGFR806-specific CAR T cells for EGFR-positive pediatric CNS tumors. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma
This clinical trial is evaluating the variation over time of visuospatial deficits in patients with parietal lobe glioma and is currently re…
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide [Phase 1, Phase 2]
Phase 1/2 trial evaluating rhIL-7-hyFc to increase lymphocyte counts in newly diagnosed glioma patients after radiation and temozolomide; re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype [Phase 2]
A Phase 2 trial of nivolumab in IDH-mutant gliomas, with and without hypermutator phenotype, has results posted on ClinicalTrials.gov.
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. [Phase 2, Phase 3]
Phase 2/3 DETERMINE trial treatment arm 05 is evaluating the combination of vemurafenib and cobimetinib in adults with BRAF-positive cancers…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Recurrent or Progressive IDH Mutant Gliomas [Phase 2]
Phase 2 trial of nivolumab for recurrent or progressive IDH-mutant gliomas has completed enrollment with results posted.
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: Infigratinib in Recurrent High-Grade Glioma Patients [EARLY_Phase 1]
Early-phase trial of infigratinib in patients with recurrent high-grade glioma, including glioblastoma, was terminated; results have been po…
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma [Phase 2]
A Phase 2 trial of solriamfetol for sleep improvement in patients with glioma (grade II–IV) including glioblastoma was terminated, with resu…
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 pediatric MATCH trial evaluating larotrectinib in patients with NTRK gene fusions has posted results; the study remains active but n…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Pharmacoscopy for Patients With Refractory Primary Brain Tumors [Phase 2]
Phase 2 clinical trial update for pharmacoscopy in patients with refractory primary brain tumors, currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-04Clinical Trial Update: Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression [Phase 2]
A Phase 2 safety study evaluating VAL-083 in combination with radiotherapy for newly diagnosed glioblastoma with unmethylated MGMT expressio…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting [Phase 2]
VAL-083 (dianhydrogalactitol) is being studied in MGMT unmethylated, bevacizumab-naive glioblastoma patients in the adjuvant or recurrent se…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma [Phase 1, Phase 2]
Kintara Therapeutics completed a Phase 1/2 safety study of VAL-083 in patients with recurrent malignant glioma, including glioma and gliobla…
-
CLINICAL_TRIALS trial_result · 2025-08-12Clinical Trial Update: Application of Cognitive Training Based on the Remind Strategy in Glioma Patients With Cognitive Impairment [NA]
A completed clinical trial study evaluating Remind Strategy-based cognitive training in glioma patients with cognitive impairment.
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas [Phase 2]
Phase 2 clinical trial evaluating retifanlimab and epacadostat with radiation and bevacizumab in recurrent gliomas has completed. Results ha…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas [EARLY_Phase 1]
This early-phase 1 trial investigates vemurafenib in pediatric patients with recurrent/refractory BRAFV600E-mutant gliomas and has completed…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
The PEAR-GLIO trial evaluating an AI R&D tool for adult gliomas and other primary brain tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-07-28Clinical Trial Update: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors [NA]
Completed clinical trial evaluating Blood-Brain Barrier Disruption (BBBD) for liquid biopsy in patients with glioblastoma or glioma, sponsor…
-
CLINICAL_TRIALS trial_result · 2025-07-11Clinical Trial Update: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma [Phase 2]
Phase 2 trial comparing proton beam therapy with intensity-modulated radiation therapy for preserving brain function in IDH-mutant grade II/…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: Blood Biomarker Signature in Glioma
The clinical trial investigating a blood biomarker signature in glioma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd [Phase 2]
Phase 2 trial evaluating talazoparib in combination with carboplatin for recurrent high-grade glioma with DDR deficiency has completed.
-
CLINICAL_TRIALS trial_result · 2025-06-05Clinical Trial Update: Evaluation of the Use of a Method "Radiomics" for DOPA PET in Gliomas
A completed clinical trial evaluating radiomics analysis of DOPA PET imaging for gliomas to assess its potential utility.
-
CLINICAL_TRIALS trial_result · 2025-05-28Clinical Trial Update: A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas [Phase 1]
A Phase 1 safety study of RTA 744 in patients with recurrent high-grade gliomas has completed.